Connect your AI

Alumis Inc. ALMS Retained Earnings

Retained Earnings at other companies

Bristol-Myers SquibbBMY

$18.29B+13.5%

AmgenAMGN

-$24.65B+9.2%

Oruka Therapeutics, Inc.ORKA

-$220.98M-111%

ANI PharmaceuticalsANIP

$6.39M+108%

Celldex TherapeuticsCLDX

-$1.89B-17.6%

ImmunomeIMNM

-$782M-40.3%

Other financials

Income statement

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

Market cap$3.17B+739%

Profitability

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alumis Inc.'s retained earnings?: Alumis Inc. (ALMS) reported retained earnings of -$994.93M in Q1 2026.
How has Alumis Inc.'s retained earnings changed year-over-year?: Alumis Inc.'s retained earnings decreased by 31.3% year-over-year, from -$757.51M to -$994.93M.
What is the long-term trend for Alumis Inc.'s retained earnings?: Over 2 years (2023 to 2025), Alumis Inc.'s retained earnings has grown at a 57.3% compound annual growth rate (CAGR), from -$364.32M to -$901.88M.
What does retained earnings mean?: Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.